S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
Man kills 4 relatives in Queens knife rampage, injures 2 officers before he's fatally shot by police
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
British military reports an explosion off the coast of Yemen in the key Bab el-Mandeb Strait
Stock market today: Shares mixed in Asia ahead of updates on jobs, inflation
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Alaska Air to buy Hawaiian Airlines in a $1.9 billion deal that may attract regulator scrutiny
Watchdog: Western arms companies failed to ramp up production capacity in 2022 due to Ukraine war
New CBOE “special perk” helps traders target income every weekend (Ad)
Alaska Air Group announces it has agreed to buy Hawaiian Airlines in a $1.9 billion deal with debt
Economists predict US inflation will keep cooling and the economy can avoid a recession
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
Man kills 4 relatives in Queens knife rampage, injures 2 officers before he's fatally shot by police
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
British military reports an explosion off the coast of Yemen in the key Bab el-Mandeb Strait
Stock market today: Shares mixed in Asia ahead of updates on jobs, inflation
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Alaska Air to buy Hawaiian Airlines in a $1.9 billion deal that may attract regulator scrutiny
Watchdog: Western arms companies failed to ramp up production capacity in 2022 due to Ukraine war
New CBOE “special perk” helps traders target income every weekend (Ad)
Alaska Air Group announces it has agreed to buy Hawaiian Airlines in a $1.9 billion deal with debt
Economists predict US inflation will keep cooling and the economy can avoid a recession
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
Man kills 4 relatives in Queens knife rampage, injures 2 officers before he's fatally shot by police
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
British military reports an explosion off the coast of Yemen in the key Bab el-Mandeb Strait
Stock market today: Shares mixed in Asia ahead of updates on jobs, inflation
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Alaska Air to buy Hawaiian Airlines in a $1.9 billion deal that may attract regulator scrutiny
Watchdog: Western arms companies failed to ramp up production capacity in 2022 due to Ukraine war
New CBOE “special perk” helps traders target income every weekend (Ad)
Alaska Air Group announces it has agreed to buy Hawaiian Airlines in a $1.9 billion deal with debt
Economists predict US inflation will keep cooling and the economy can avoid a recession
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
Man kills 4 relatives in Queens knife rampage, injures 2 officers before he's fatally shot by police
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
British military reports an explosion off the coast of Yemen in the key Bab el-Mandeb Strait
Stock market today: Shares mixed in Asia ahead of updates on jobs, inflation
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Alaska Air to buy Hawaiian Airlines in a $1.9 billion deal that may attract regulator scrutiny
Watchdog: Western arms companies failed to ramp up production capacity in 2022 due to Ukraine war
New CBOE “special perk” helps traders target income every weekend (Ad)
Alaska Air Group announces it has agreed to buy Hawaiian Airlines in a $1.9 billion deal with debt
Economists predict US inflation will keep cooling and the economy can avoid a recession

Krystal Biotech Stock Price, News & Analysis (NASDAQ:KRYS)

$106.26
+2.03 (+1.95%)
(As of 12/1/2023 ET)
Compare
Today's Range
$103.69
$106.30
50-Day Range
$96.00
$122.15
52-Week Range
$69.81
$132.68
Volume
188,759 shs
Average Volume
364,454 shs
Market Capitalization
$3.00 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$146.56

Krystal Biotech MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
37.9% Upside
$146.56 Price Target
Short Interest
Bearish
7.34% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.87
Upright™ Environmental Score
News Sentiment
1.16mentions of Krystal Biotech in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$3.18 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($3.89) to ($0.58) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.52 out of 5 stars

Medical Sector

152nd out of 957 stocks

Biological Products, Except Diagnostic Industry

21st out of 157 stocks


KRYS stock logo

About Krystal Biotech Stock (NASDAQ:KRYS)

Krystal Biotech, Inc., a biotechnology company, develops and commercializes genetic medicines for patients with rare diseases in the United States. It develops beremagene geperpavec (B-VEC) for dystrophic epidermolysis bullosa; KB105 for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for netherton syndrome; and KB407 for Cystic Fibrosis. The company also develops KB408 for Alpha-1 antitrypsin deficiency; and KB301 for aesthetic skin conditions. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

KRYS Stock Price History

KRYS Stock News Headlines

Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
Krystal Biotech Inc KRYS
This Stock Has Quadrupled in 5 Years. Can It Do It Again?
Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
Q3 2023 Krystal Biotech Inc Earnings Call
Krystal Biotech Q3 2023 Earnings Preview
KRYS Oct 2023 110.000 call
See More Headlines
Receive KRYS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Krystal Biotech and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/06/2023
Today
12/03/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/26/2024

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KRYS
Fax
N/A
Employees
210
Year Founded
2017

Price Target and Rating

Average Stock Price Target
$146.56
High Stock Price Target
$160.00
Low Stock Price Target
$118.00
Potential Upside/Downside
+37.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
9 Analysts

Profitability

Net Income
$-139,980,000.00
Pretax Margin
-348.43%

Debt

Sales & Book Value

Annual Sales
$8.56 million
Book Value
$26.80 per share

Miscellaneous

Free Float
23,411,000
Market Cap
$3.00 billion
Optionable
Not Optionable
Beta
0.84

Social Links

5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report














KRYS Stock Analysis - Frequently Asked Questions

Should I buy or sell Krystal Biotech stock right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Krystal Biotech in the last twelve months. There are currently 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" KRYS shares.
View KRYS analyst ratings
or view top-rated stocks.

What is Krystal Biotech's stock price target for 2024?

9 equities research analysts have issued 12-month price targets for Krystal Biotech's shares. Their KRYS share price targets range from $118.00 to $160.00. On average, they expect the company's share price to reach $146.56 in the next year. This suggests a possible upside of 37.9% from the stock's current price.
View analysts price targets for KRYS
or view top-rated stocks among Wall Street analysts.

How have KRYS shares performed in 2023?

Krystal Biotech's stock was trading at $79.22 at the beginning of the year. Since then, KRYS stock has increased by 34.1% and is now trading at $106.26.
View the best growth stocks for 2023 here
.

When is Krystal Biotech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 26th 2024.
View our KRYS earnings forecast
.

How were Krystal Biotech's earnings last quarter?

Krystal Biotech, Inc. (NASDAQ:KRYS) released its quarterly earnings results on Monday, November, 6th. The company reported $2.79 earnings per share for the quarter, topping the consensus estimate of ($1.10) by $3.89. The firm earned $8.60 million during the quarter, compared to analysts' expectations of $6.29 million. The company's quarterly revenue was up 8500.0% compared to the same quarter last year. During the same period in the prior year, the firm posted ($1.17) EPS.

What other stocks do shareholders of Krystal Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Krystal Biotech investors own include Pfizer (PFE), Allena Pharmaceuticals (ALNA), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Corbus Pharmaceuticals (CRBP), VBI Vaccines (vbiv), Verastem (VSTM), CRISPR Therapeutics (CRSP), Editas Medicine (EDIT) and NVIDIA (NVDA).

When did Krystal Biotech IPO?

(KRYS) raised $30 million in an initial public offering (IPO) on Wednesday, September 20th 2017. The company issued 3,000,000 shares at $9.00-$11.00 per share. Ladenburg Thalmann served as the underwriter for the IPO.

Who are Krystal Biotech's major shareholders?

Krystal Biotech's stock is owned by many different retail and institutional investors. Top institutional shareholders include FMR LLC (9.32%), Redmile Group LLC (7.10%), Lord Abbett & CO. LLC (2.38%), Jennison Associates LLC (1.22%), Morgan Stanley (1.02%) and Skandinaviska Enskilda Banken AB publ (0.87%). Insiders that own company stock include Andrew C Orth, Daniel Janney, Dino A Rossi, Kathryn Romano, Krish S Krishnan and Suma Krishnan.
View institutional ownership trends
.

How do I buy shares of Krystal Biotech?

Shares of KRYS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:KRYS) was last updated on 12/3/2023 by MarketBeat.com Staff

My Account -